Here is What to Know Beyond Why McKesson Corporation (MCK) is a Trending Stock
McKesson (MCK), a prescription drug distributor, has gained 12.6% over the past month, outperforming the S&P 500's -3.7% decline. The company has a Zacks Rank #2 (Buy) rating based on positive earnings estimate revisions. Current quarter EPS is expected at $10.79 (+15.5% YoY), with full-year earnings projected at $45.78 (+17.1% YoY). Revenue growth is forecasted at 8% for the current quarter and fiscal year. McKesson has consistently beaten consensus estimates and trades at a valuation discount to peers (Value Style Score: B).


